Cardiome Pharma (CRME) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
March 13, 2018 4:00 PM EDTManagement to Host Conference Call and Webcast Today, March 13, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)
NASDAQ: CRMEÂ Â TSX: COM
VANCOUVER, March 13, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today reported financial results for its fourth quarter and year ended December 31, 2017 and commented on recent accomplishments and plans.
William Hunter, MD, CEO and President of Cardiome, commented, "Cardiome achieved a number of important milestones in 2017, including the commercialization of two new... More
